ClinicalTrials.gg
Not yet recruitingNCT07854366Updated Oct 16, 2026

SmoothCore Orthokeratology Plus M.O.V.E. Lenses vs. M.O.V.E. Lenses Alone for Myopia Control in Children With High Myopia

An interventional study of SmoothCore Technology Orthokeratology Combined with M.O.V.E. Lenses and M.O.V.E. Lenses Alone in High Myopia, sponsored by Beijing Tongren Hospital. Not yet recruiting. Open to participants aged 8 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Beijing Tongren Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
8 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Myopia by Beijing Tongren Hospital — 10 open to participants now, 11 under way, none of them phase 3. Myopia · Beijing Tongren Hospital.

Planned enrollment
13th of 17
100 · median 120
Started
2026
with 5 others
No phase
14 of 22
6 open now
Primary completion
2028-04
later than 9 of 10 live
Registered
19th of 22
by date

Among the 22 studies in Myopia by Beijing Tongren Hospital, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2026, is one of 14 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 19th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

10 of the 22 studies in Myopia by Beijing Tongren Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 8 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Myopia by Beijing Tongren Hospital, or all of them as a file.
02

Study summary

This clinical trial aims to determine whether a combination of overnight orthokeratology lenses and daytime myopia-control spectacles is more effective than myopia-control spectacles alone in slowing myopia progression and improving vision-related quality of life in children aged 8-14 years with high myopia. Orthokeratology lenses are contact lenses designed to temporarily reshape the anterior surface of the eye during sleep. The study will also asess the safety of this combined treatment.The main questions it seeks to answer are:

  • Does the combined treatment slow myopia progression over 12 months more effectively than myopia-control spectacles alone?
  • What ocular problems occur with each treatment, and how well do children adhere to the prescribed lens-wearing schedules?

The researchers will compare SmoothCore orthokeratology lenses combined with M.O.V.E. myopia-control spectacle lenses with the same spectacle lenses used alone. A total of 100 children will be randomly assigned to one of the two groups, with an equal chance of being allocated to either group.

Participants will:

  • Wear their assigned spectacle lenses for at least 10 hours per day for 12 months. Children in the combined-treatment group will also wear orthokeratology lenses for at least 8 hours per night on at least 5 nights per week.
  • Attend clinic visits at baseline and at 1 day, 1 week, and 1, 3, 6, and 12 months for scheduled eye examinations and measurements.
  • Keep a record of lens-wearing time and any eye discomfort, with assitance from a parent or guardian.
  • Complete questionnaires about vision-related daily activities and satisfaction with their lenses.
Read the detailed description

Childhood high myopia is associated with continued axial elongation and an increased lifetime risk of sight-threatening ocular disease. Overnight orthokeratology temporarily reshapes the cornea and may slow axial elongation; however, children with high myopia may still require daytime spectacles to correct residual refractive error. Whether combining orthokeratology with myopia-control spectacles offers additional benefit over myopia-control spectacles alone remains uncertain.

This single-center, prospective, parallel-group, exploratory superiority randomized controlled trial will enroll 100 children aged 8-14 years with high myopia. Participants will be randomized in a 1:1 ratio using a computer-generated, variable-block sequence stratified by age. Participants, guardians, and lens-fitting personnel will be unmasked; outcome assessors and statistical analysts will remain masked until database lock.

The combined-treatment group will wear SmoothCore orthokeratology lenses for at least 8 hours per night on at least 5 nights per week, together with M.O.V.E. myopia-control spectacles for at least 10 hours per day. Orthokeratology will provide partial correction according to the approved correction range and individual ocular characteristics, while daytime spectacles will correct any residual refractive error. The spectacle-only group will wear the same spectacle lens model and optical design, with full central refractive correction, for at least 10 hours per day. Study lenses will be supplied by the study site and used within their NMPA-approved indications. Prescriptions will be adjusted according to standardized criteria.

Participants will undergo screening and assessments at baseline, 1 day, 1 week, and 1, 3, 6, and 12 months. Adherence will be assessed using lens-wear diaries, questionnaires, and where applicable, contact lens care-solution usage records. Ocular safety assessments will include slit-lamp examination, corneal staining and topography, intraocular pressure measurement, corneal endothelial assessment, and adverse event monitoring. Vision-related quality of life and lens satisfaction will also be evaluated.

The primary outcome is the change in study-eye axial length from baseline to month 12 and change in vision-related quality of life at 3, 6 and 12 months. The study eye will be selected before randomization: the qualifying eye if only one meets the high-myopia criterion, or the right eye if both qualify. Additional outcomes include refractive and corneal changes, adherence, quality of life, satisfaction, and safety. Refractive outcomes will be interpreted as exploratory because orthokeratology alters corneal shape.

The primary analysis will follow the intention-to-treat principle using analysis of covariance adjusted for baseline axial length, age, and baseline spherical equivalent refraction. Sensitivity and supportive analyses will assess the robustness of the findings. Safety will be analyzed according to treatment actually received among participants who receive at least one study intervention.

03

Conditions studied

  • High Myopia

Browse trials for

Keywords

  • High Myopia
  • Orthokeratology
  • Myopia-Control Spectacle Lenses
  • Axial Length
  • Myopia Control
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
8 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 8 to 14 years, regardless of sex.
  • Cycloplegic spherical equivalent refraction between -9.00 D and -5.00 D in at least one eye; astigmatism ≤1.50 D in each eye; and anisometropia ≤ 2.00 D;the power in the most negative principal meridian of the spectacle prescription ≥ -9.00 D.
  • Normal corneal topography and corneal curvature between 39.00 and 48.00 D, meeting the fitting requirements for the study's orthokeratology lenses. Corneal endothelial cell density of at least 2,000 cells/mm², with no other significant corneal endothelial abnormalities.
  • No use of low-concentration atropine, repeated low-level red-light therapy, orthokeratology lenses, spectacle lenses with special optical designs for myopia control or vision training for myopia control within the 3 months before screening.
  • Intraocular pressure between 10 and 21 mmHg and best-corrected visual acuity of 20/25 or better in each eye.
  • No ocular or systematic disease that could affect vision or study assessments.
  • Written from a legal guardian and assent from the child after an age-appropriate explanation of the study.
  • The child and legal guardian are willing to accept random assignment and are able to comply with the prescribed lens wear, lens care, and follow-up requirements.

Exclusion criteria

Exclusion Criteria:

  • Inability to be safely fitted with orthokeratology lenses.
  • Active ocular surface disease, keratoconus, or other corneal abnormalities.
  • tear film abnormalities or corneal staining.
  • Amblyopia, strabismus, glaucoma, uveitis, cataract, retinal disease, or fundus changes associated with pathologic myopia.
  • A history of ocular surgery or trauma that could affect corneal shape or study assessments.
  • Any systemic disease that could affect ocular health, the safety of lens wear, or adherence to study requirements.
  • Current use of medications that significantly affect refraction, axial length, accommodation, or the ocular surface.
  • Allergy to study-related lenses, lens care solutions, or medications used for study examinations.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    SmoothCore Technology Orthokeratology Combined with M.O.V.E. Lenses

    Device: SmoothCore Technology Orthokeratology Combined with M.O.V.E. Lenses

  • Active comparator
    M.O.V.E. Lenses Alone

    Device: M.O.V.E. Lenses Alone

Interventions

  • DeviceSmoothCore Technology Orthokeratology Combined with M.O.V.E. Lenses

    Participants will wear NMPA-approved orthokeratology (OK) lenses suitable for their corneal characteristics and refractive status overnight, with a target wearing schedule of at least 5 nights per week and at least 8 hours per night. Partial correction will be provided according to the approved correction range, corneal topography, and refractive status. During waking hours, participants will wear the study-specified model of M.O.V.E. spectacle lenses to correct residual refractive error following orthokeratology and provide the intended optical defocus, with a target wearing time of at least 10 hours per day. Prescriptions for both the OK lenses and M.O.V.E. lenses will be determined by trained study ophthalmologists or optometrists in accordance with standardized operating procedures.

  • DeviceM.O.V.E. Lenses Alone

    Participants will wear M.O.V.E. spectacle lenses of the same brand, model, and optical design as the daytime lenses used in the experimental group. The central prescription will provide full correction based on cycloplegic refraction, with a target wearing time of at least 10 hours per day. Visual acuity and refractive status will be reassessed at scheduled visits, and the spectacle prescription will be updated when the predefined adjustment criteria are met.

06

What researchers measure

Primary outcomes

  1. Axial elongation

    Change in axial length from baseline to month 12 (ΔAL, mm) serves as the primary outcome measure. Axial length will be measured in millimeters using the LENSTAR LS 900 optical biometer,

    Time frame: Baseline and months 3, 6, 12

Secondary outcomes

  1. Vision-related quality of life (Pediatric Refractive Error Profile 2,PREP2)

    Scores on the Pediatric Refractive Error Profile 2 (PREP2) range from 0 to 100, with higher scores indicating better vision-related quality of life.

    Time frame: Baseline and months 1, 3, 6 and 12

  2. Cycloplegic refraction

    Cycloplegic refraction will be measured using an autorefractor after cycloplegia and calculated as spherical power plus one-half of cylindrical power, in diopters (D). Change will be calculated as the follow-up value minus the baseline value.

    Time frame: Baseline and months 6, 12

  3. Corneal higher-order aberrations

    Anterior corneal higher-order aberrations will be measured using the Pentacam system. The root mean square (RMS) of Zernike terms of orders 3 through 6 will be calculated over a standardized 6.0 mm analysis diameter and reported in micrometers (µm).

    Time frame: Baseline and months 3,6, 12

  4. Pupil diameter

    Pupil diameter will be measured using the LENSTAR LS 900 optical biometer and reported in millimeters (mm).

    Time frame: Baseline and months 3,6, 12

  5. Subfoveal choroidal thickness and choroidal vessel density

    Subfoveal choroidal thickness will be measured using optical coherence tomography and reported in micrometers (µm). Flow density will be defined as the percentage of the analyzable region occupied by detected flow signal in the choriocapillaris slab. Assessments will be performed between 8:00 and 10:00 a.m. to reduce variation associated with time of day.

    Time frame: Baseline and months 1, 3, 6,12

  6. Best-corrected visual acuity (BCVA) and presenting visual acuity

    The best visual acuity achievable with optimal refractive correction and presenting visual acuity, expressed as the logarithm of the minimum angle of resolution (logMAR). Scores range from -0.3 to 1.0 logMAR, with lower values indicating better visual acuity. A value of 0.0 logMAR corresponds to decimal visual acuity of 1.0.

    Time frame: Baseline and months 3, 6,12

07

Study locations

No study locations are listed for this record.

08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2028, 17 months later.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 17 months is below that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Oct 2, 2026
StartEst.
Oct 8, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Oct 8, 2026
Oct 13, 2026
Eligibility
Criteria revised in 2 updates
What changed on Oct 13, 2026
Inclusion criteria
  • RemovedAt least one eye has an equivalent spherical refractive error of -10.00--6.00 D; Binocular astigmatism ≤1.50 D; Anisometropia ≤2.00 D
  • RemovedPredominantly axial myopia with reliable axial length measurements
  • AddedChildren aged 8 to 14 years, regardless of sex.
  • AddedCycloplegic spherical equivalent refraction between -9.00 D and -5.00 D in at least one eye; astigmatism ≤1.50 D in each eye; and anisometropia ≤ 2.00 D.
  • EditedNormal corneal topography (and corneal curvature: between 39.00- and 48.00 D), meeting the fitting requirements for fittingthe study's orthokeratology lenses for this study. Corneal endothelial cell density of at least 2,000 cells/mm², with no other significant corneal endothelial abnormalities.
  • EditedNo administrationuse of low-concentration atropine, repeated low-intensitylevel red -light therapy (RLRL), orthokeratology lenses, specially designed spectacles, multifocal/dioptric contactspectacle lenses, with special optical designs for myopia control or any visual functionvision training related tofor myopia control within the preceding 63 months before screening.
  • RemovedBimanual intraocular pressure: 10-21 mmHg
  • EditedBestIntraocular pressure between 10 and 21 mmHg and best-corrected visual acuity ≥of 20/25 or better in each eye.
  • RemovedCorneal endothelial cell density ≥2000 cells/mm² with no other significant endothelial abnormalities
  • RemovedNo ocular diseases that would affect visual acuity or be relevant to this study
  • RemovedParticipants and their guardians must voluntarily participate in the study and sign an informed consent form
  • RemovedParticipants must be able to undergo randomization and wear the prescribed lenses, follow the required care instructions, and attend scheduled follow-up visits.
  • AddedNo ocular or systematic disease that could affect vision or study assessments.
  • AddedWritten informed consent from a legal guardian and assent from the child after an age-appropriate explanation of the study.
  • AddedThe child and legal guardian are willing to accept random assignment and are able to comply with the prescribed lens wear, lens care, and follow-up requirements.
Exclusion criteria
  • RemovedImpossibility of safely fitting orthokeratology lenses
  • AddedInability to be safely fitted with orthokeratology lenses.
  • Editedpresence of activeActive ocular surface disordersdisease, keratoconus, or other corneal abnormalities; significant abnormalities in tear film or corneal staining.
  • AddedClinically significant tear film abnormalities or corneal staining.
  • Editedpresence of amblyopiaAmblyopia, strabismus, glaucoma, uveitis, cataractscataract, retinal diseasesdisease, or pathological fundus changes due toassociated with pathologic myopia.
  • EditedA history of ocular surgery or trauma that may have alteredcould affect corneal morphologyshape or influenced the study evaluationassessments.
  • ChangedBefore presence of systemic diseases that may affect ocular health, lens fitting safety, or treatment complianceNow Any systemic disease that could affect ocular health, the safety of lens wear, or adherence to study requirements.
  • EditedcurrentCurrent use of medications that significantly impact refractive statusaffect refraction, axial length, accommodation, or the ocular surface condition.
  • EditedallergyAllergy to the study-related lenses, lens care solutions, or diagnostic agentsmedications used for study examinations.
  • Removedplanned use of myopia control measures outside those specified in the study protocol during the study period
  • Removedother circumstances deemed unsuitable for participation by the investigator, with the specific reasons documented.
What changed on Oct 16, 2026
Inclusion criteria
  • EditedCycloplegic spherical equivalent refraction between -9.00 D and -5.00 D in at least one eye; astigmatism ≤1.50 D in each eye; and anisometropia ≤ 2.00 D;the power in the most negative principal meridian of the spectacle prescription ≥ -9.00 D.
across 2 updates, Oct 13, 2026 – Oct 16, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 13, 2026
  • AddedAxial elongationTime frame: Baseline and months 3, 6, 12
  • AddedVision-related quality of life and satisfaction (National Eye Institute 25-Item Visual Function Questionnaire,NEI VFQ-25)Time frame: Baseline and months 3, 6 and 12
  • RemovedAxial Length,ALTime frame: Month3,Month6,Month12,
What changed on Oct 16, 2026
  • RemovedVision-related quality of life and satisfaction (National Eye Institute 25-Item Visual Function Questionnaire,NEI VFQ-25)Time frame: Baseline and months 3, 6 and 12
across 2 updates, Oct 13, 2026 – Oct 16, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 13, 2026
  • EditedSubretinalSubfoveal choroidal thickness and choroidal blood flowvessel densityTime frame: month1,3,6,12 → Baseline and months 1, 3, 6,12
  • EditedBest -corrected visual acuity (BCVA) and presenting visual acuityTime frame: month6,12 → Baseline and months 3, 6,12
  • AddedCycloplegic refractionTime frame: Baseline and months 6, 12
  • AddedPupil diameterTime frame: Baseline and months 3,6, 12
  • AddedAccommodative and binocular visual functionTime frame: Baseline and months 3,6, 12
  • RemovedEquivalent spherical power (SER)Time frame: month6,12
  • RemovedMeasure pupil sizeTime frame: month6,12
  • RemovedNational Eye Institute 25-Item Visual Function QuestionnaireTime frame: month6,12
  • RemovedAmplitude of Accommodation,AATime frame: month6,12
  • RemovedAccommodative Facility,AFTime frame: month6,12
  • RemovedPositive Relative AccommodationTime frame: month6,12
  • RemovedNegative Relative AccommodationTime frame: month6,12
  • RemovedNear Horizontal HeterophoriaTime frame: month6,12
  • RemovedAccommodative LagTime frame: month6,12
  • Time frameCorneal higher-order aberrationsmonth6,12 → Baseline and months 3,6, 12
  • DescriptionCorneal higher-order aberrations: how it is measured was reworded
What changed on Oct 16, 2026
  • ChangedBefore Accommodative and binocular visual functionNow Vision-related quality of life (Pediatric Refractive Error Profile 2,PREP2)Time frame: Baseline and months 3,6, 12 → Baseline and months 1, 3, 6 and 12
across 2 updates, Oct 13, 2026 – Oct 16, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Oct 16, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedCycloplegic spherical equivalent refraction between -9.00 D and -5.00 D in at least one eye; astigmatism ≤1.50 D in each eye; and anisometropia ≤ 2.00 D;the power in the most negative principal meridian of the spectacle prescription ≥ -9.00 D.
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedVision-related quality of life and satisfaction (National Eye Institute 25-Item Visual Function Questionnaire,NEI VFQ-25)Time frame: Baseline and months 3, 6 and 12
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Accommodative and binocular visual functionNow Vision-related quality of life (Pediatric Refractive Error Profile 2,PREP2)Time frame: Baseline and months 3,6, 12 → Baseline and months 1, 3, 6 and 12
  2. Oct 13, 2026
    Start date Oct 1, 2026→Oct 8, 2026
    Eligibility 3 inclusion criteria edited, 5 added, 7 removed; 6 exclusion criteria edited, 2 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAt least one eye has an equivalent spherical refractive error of -10.00--6.00 D; Binocular astigmatism ≤1.50 D; Anisometropia ≤2.00 D
    • RemovedPredominantly axial myopia with reliable axial length measurements
    • AddedChildren aged 8 to 14 years, regardless of sex.
    • AddedCycloplegic spherical equivalent refraction between -9.00 D and -5.00 D in at least one eye; astigmatism ≤1.50 D in each eye; and anisometropia ≤ 2.00 D.
    • EditedNormal corneal topography (and corneal curvature: between 39.00- and 48.00 D), meeting the fitting requirements for fittingthe study's orthokeratology lenses for this study. Corneal endothelial cell density of at least 2,000 cells/mm², with no other significant corneal endothelial abnormalities.
    • EditedNo administrationuse of low-concentration atropine, repeated low-intensitylevel red -light therapy (RLRL), orthokeratology lenses, specially designed spectacles, multifocal/dioptric contactspectacle lenses, with special optical designs for myopia control or any visual functionvision training related tofor myopia control within the preceding 63 months before screening.
    • RemovedBimanual intraocular pressure: 10-21 mmHg
    • EditedBestIntraocular pressure between 10 and 21 mmHg and best-corrected visual acuity ≥of 20/25 or better in each eye.
    • RemovedCorneal endothelial cell density ≥2000 cells/mm² with no other significant endothelial abnormalities
    • RemovedNo ocular diseases that would affect visual acuity or be relevant to this study
    • RemovedParticipants and their guardians must voluntarily participate in the study and sign an informed consent form
    • RemovedParticipants must be able to undergo randomization and wear the prescribed lenses, follow the required care instructions, and attend scheduled follow-up visits.
    • AddedNo ocular or systematic disease that could affect vision or study assessments.
    • AddedWritten informed consent from a legal guardian and assent from the child after an age-appropriate explanation of the study.
    • AddedThe child and legal guardian are willing to accept random assignment and are able to comply with the prescribed lens wear, lens care, and follow-up requirements.
    Exclusion criteria
    • RemovedImpossibility of safely fitting orthokeratology lenses
    • AddedInability to be safely fitted with orthokeratology lenses.
    • Editedpresence of activeActive ocular surface disordersdisease, keratoconus, or other corneal abnormalities; significant abnormalities in tear film or corneal staining.
    • AddedClinically significant tear film abnormalities or corneal staining.
    • Editedpresence of amblyopiaAmblyopia, strabismus, glaucoma, uveitis, cataractscataract, retinal diseasesdisease, or pathological fundus changes due toassociated with pathologic myopia.
    • EditedA history of ocular surgery or trauma that may have alteredcould affect corneal morphologyshape or influenced the study evaluationassessments.
    • ChangedBefore presence of systemic diseases that may affect ocular health, lens fitting safety, or treatment complianceNow Any systemic disease that could affect ocular health, the safety of lens wear, or adherence to study requirements.
    • EditedcurrentCurrent use of medications that significantly impact refractive statusaffect refraction, axial length, accommodation, or the ocular surface condition.
    • EditedallergyAllergy to the study-related lenses, lens care solutions, or diagnostic agentsmedications used for study examinations.
    • Removedplanned use of myopia control measures outside those specified in the study protocol during the study period
    • Removedother circumstances deemed unsuitable for participation by the investigator, with the specific reasons documented.
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedAxial elongationTime frame: Baseline and months 3, 6, 12
    • AddedVision-related quality of life and satisfaction (National Eye Institute 25-Item Visual Function Questionnaire,NEI VFQ-25)Time frame: Baseline and months 3, 6 and 12
    • RemovedAxial Length,ALTime frame: Month3,Month6,Month12,
    Secondary outcomes 2 edited, 1 time frame changed, 3 added, 9 removed, 1 description edited
    What changed in the outcomes
    • EditedSubretinalSubfoveal choroidal thickness and choroidal blood flowvessel densityTime frame: month1,3,6,12 → Baseline and months 1, 3, 6,12
    • EditedBest -corrected visual acuity (BCVA) and presenting visual acuityTime frame: month6,12 → Baseline and months 3, 6,12
    • AddedCycloplegic refractionTime frame: Baseline and months 6, 12
    • AddedPupil diameterTime frame: Baseline and months 3,6, 12
    • AddedAccommodative and binocular visual functionTime frame: Baseline and months 3,6, 12
    • RemovedEquivalent spherical power (SER)Time frame: month6,12
    • RemovedMeasure pupil sizeTime frame: month6,12
    • RemovedNational Eye Institute 25-Item Visual Function QuestionnaireTime frame: month6,12
    • RemovedAmplitude of Accommodation,AATime frame: month6,12
    • RemovedAccommodative Facility,AFTime frame: month6,12
    • RemovedPositive Relative AccommodationTime frame: month6,12
    • RemovedNegative Relative AccommodationTime frame: month6,12
    • RemovedNear Horizontal HeterophoriaTime frame: month6,12
    • RemovedAccommodative LagTime frame: month6,12
    • Time frameCorneal higher-order aberrationsmonth6,12 → Baseline and months 3,6, 12
    • DescriptionCorneal higher-order aberrations: how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07854366
Responsible party
Shi-Ming Li (Professor and Director, Medical Optometry Center, Beijing Tongren Hospital) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 8, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion